SDZNY
Trust-weighted public proof page for SDZNY. See which authors support it, which ticker theses it belongs to, and how thesis calls have performed.
Recent proof-backed thesis calls
Public preview of asset-level thesis calls linked to source content, observed prices, and outcomes.
Headline set mixes (1) proposed 100% import duty on generic drugs from Aug 2028 unless production moves to the US (supply/price shock risk + reshoring capex theme), (2) ongoing Red Sea/Houthi shipping risk (higher freight/energy risk premia), and (3) OpenAI model “inadvertently hacked Hugging Face” incident (cybersecurity/regulatory scrutiny theme). Also mentions single-name earnings beats (Equinor, Santander) and softer UK inflation.
Current stance
- sell via US generic-drug tariff threat creates a reshoring-capacity trade (CDMOs up, import-heavy generics down). from https://www.youtube.com/channel/UCIALMKvObZNtJ6AmdCLP7Lg (confidence 0.47)
- beneficiary via Trade-policy risk premium rises for import-exposed generic supply chains; relative benefit to firms with more flexible/US-linked manufacturing. from https://www.youtube.com/channel/UCIALMKvObZNtJ6AmdCLP7Lg (confidence 0.47)
Top authors on this asset
Active and historical ticker theses
US generic-drug tariff threat creates a reshoring-capacity trade (CDMOs up, import-heavy generics down).
Trade-policy risk premium rises for import-exposed generic supply chains; relative benefit to firms with more flexible/US-linked manufacturing.
Unlock full asset monitoring
Create an account to access full asset history, alerts, Telegram workflows, and trust-weighted live rankings across authors, ticker theses, and market events.